反应详情

To a stirred solution of (S)-ethyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-hydroxyphenyl)-2,6-dimethylpyridin-3-yl)acetate (0.04 g, 0.085 mmol), 2-(4-methoxyphenyl)ethanol (0.065 g, 0.427 mmol) and Ph3P (0.067 g, 0.256 mmol) in THF (5 mL) was added DEAD (0.041 ml, 0.256 mmol) at 0° C. After 1 h, the cold bath was removed and stirred for 16 h at rt. Then, the reaction mixture was concentrated and the residue purified by prep-HPLC to afford (S)-ethyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-methoxyphenethoxy)phenyl)-2,6-dimethylpyridin-3-yl)acetate (0.0362 g, 0.060 mmol, 70.4% yield) as white solid. 1H NMR (500 MHz, CDCl3) δ 7.27-7.23 (m, 2H), 7.17-7.13 (m, 1H), 7.09-7.04 (m, 1H), 7.00-6.95 (m, 2H), 6.92-6.88 (m, 2H), 6.08 (s, 1H), 4.29-4.12 (m, 4H), 3.83 (s, 3H), 3.18 (br. s., 1H), 3.11 (t, J=7.1 Hz, 2H), 2.88 (br. s., 1H), 2.61 (s, 3H), 2.28 (br.s., 1H), 2.20 (s, 3H), 2.12-2.00 (m, 1H), 1.71-1.81 (m, 1H), 1.60-1.49 (m, 1H), 1.41-1.32 (m, 1H), 1.26 (t, J=7.1 Hz, 3H), 1.21 (s, 9H), 1.08-1.12 (m, 1H), 0.90 (br.s., 2H), 0.67 (br. s., 2H). LCMS (M+H)=603.5.

1. customthe cold bath was removed
2. concentrationThen, the reaction mixture was concentrated
3. customthe residue purified by prep-HPLC